-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

Benzinga·06/08/2026 09:52:20
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.75 to $10.25.